01

29.2% complete response rate with lifileucel plus pembrolizumab

In a 24-patient Phase II analysis, lifileucel plus pembrolizumab achieved 62.5% tumor shrinkage and 29.2% complete response in advanced melanoma; a Phase III comparison is underway.